CD274 and neoplasm: Low-PD-L1 patients in the durvalumab plus tremelimumab arm had a notably lower pCR than high-PD-L1 patients (14.3% versus 57%), and there was no difference in pCR in the patients with “hot” tumours treated by chemotherapy.